Johnson & Johnson

NYSE:JNJ   3:59:59 PM EDT
165.24
-1.34 (-0.80%)
5:02:37 PM EDT: $165.24 0.00 (0.00%)
Products, Regulatory

Janssen Says New Phase 3 Study Results Show Imbruvica(Ibrutinib)-Based Combination Regimen As All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival In Adult Patients

Published: 06/12/2021 11:16 GMT
Johnson & Johnson (JNJ) - Janssen Says New Phase 3 Study Results Show Imbruvica® (ibrutinib)-based Combination Regimen As an All-oral Fixed-duration Treatment Demonstrated Superior Progression-free Survival in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia.
Janssen - Glow Study Presented As a Late-breaking Abstract at European Hematology Association (eha) Virtual Congress.